02171.HK
CARsgen Therapeutics Holdings Limited
HKSE · Healthcare · Biotechnology · CN
HKD 12.75
+3.66%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenHKD 12.42
From 52W high−52.03%
Volume3.54M
Market capHKD 7.36B
P/E (TTM)—
P/S (TTM)46.1x
Div yield—
Key dataSep 18, 2026
Open
HKD 12.42
From 52W high
−52.03%
Volume
3.54M
Market cap
HKD 7.36B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−22.9x
P/E (TTM)
—
RSI (14)
43.1
MomentumView details →
1D Return
+3.66%
YTD Return
−14.14%
Similar companies
Latest newsMore news →
CARsgen Therapeutics announced at its results meeting on August 19, 2026, that Kailimei has been prescribed at Beijing Gaobo Hospital, with cell collection completed at Fudan University-affiliated Zhongshan Hospital and at Jiahui International Cancer Center for a foreign patient.32d agoCARsgen Therapeutics reported interim results for the six months ended June 2026, with revenue of RMB 61.92 million, up 21.5% year-on-year, and a narrowed net loss of RMB 66.66 million, compared with a loss of RMB 75.34 million in the same period last year.33d agoCarsgen Therapeutics announced that its universal CAR-T therapy CT1190B received clinical trial approval from China's National Medical Products Administration for the treatment of relapsed/refractory large B-cell lymphoma.45d ago